Literature DB >> 9031720

Mechanism of thrombin inhibition by antithrombin and heparin cofactor II in the presence of heparin.

R M Maaroufi1, M Jozefowicz, J Tapon-Bretaudière, A M Fischer.   

Abstract

The kinetics of thrombin inhibition by antithrombin (AT) and heparin cofactor II (HC II) were analysed as a function of the heparin concentration, from 10(-9) to 10(-4) M. The initial concentrations of inhibitor (l) and thrombin (E) were set at equimolar levels (CI = CE = 10(-8) M). The experimental data indicate that the reaction of thrombin inhibition was second-order both in the absence and in the presence of heparin, and that the apparent rate constant increased at heparin concentrations ranging from 10(-9) to 10(-6) M and decreased at higher concentrations. The data fit with the kinetic model established by Jordan et al. [J. Biol. Chem. 1979, 254, 2902-2913] for the catalysis of the thrombin-AT reaction by a low-molecular-weight heparin fraction. In this model, heparin (H) binds quickly to the inhibitor (I) and forms a heparin-inhibitor complex (HI), which is more reactive than the free inhibitor towards thrombin, leading to the formation of an inactive inhibitor-thrombin complex (I*E) and the release of free heparin, in a second step which is rate limiting. KH,I, the dissociation constant of HI, and k, the second-order rate constant of free thrombin inhibition by HI, were found to be 3.7 x 10(-7) M and 1.3 x 10(9) M-1 min-1, respectively, for AT, compared to a KH,I of 2.0 x 10(-6) M and k of 6.4 x 10(9) M-1 min-1 for HC II. These data indicate that heparin-HC II complex reactivity is greater than that of the heparin-AT complex towards thrombin, whereas heparin affinity is stronger for AT. At heparin concentrations higher than 10(-6) M, the decrease in the reaction rate was in keeping with the formation of a heparin-thrombin complex (HE), whose inactivation by the heparin-inhibitor complex (HI) is slower than that of the free protease.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9031720     DOI: 10.1016/s0142-9612(96)00125-1

Source DB:  PubMed          Journal:  Biomaterials        ISSN: 0142-9612            Impact factor:   12.479


  6 in total

1.  Investigation of the heparin-thrombin interaction by dynamic force spectroscopy.

Authors:  Congzhou Wang; Yingzi Jin; Umesh R Desai; Vamsi K Yadavalli
Journal:  Biochim Biophys Acta       Date:  2015-01-31

Review 2.  Revisiting the Pharmacology of Unfractionated Heparin.

Authors:  Abdallah Derbalah; Stephen Duffull; Fiona Newall; Katie Moynihan; Hesham Al-Sallami
Journal:  Clin Pharmacokinet       Date:  2019-08       Impact factor: 6.447

3.  In vitro and in vivo effects of hemodilution on kaolin-based activated clotting time predicted heparin requirement using a heparin dose-response technique.

Authors:  Junko Ichikawa; Satoshi Hagihira; Testu Mori; Mitsuharu Kodaka; Keiko Nishiyama; Makoto Ozaki; Makiko Komori
Journal:  J Anesth       Date:  2016-08-08       Impact factor: 2.078

4.  An antithrombin-heparin complex increases the anticoagulant activity of fibrin clots.

Authors:  Lesley J Smith; Tracy Anne Mewhort-Buist; Leslie R Berry; Anthony K C Chan
Journal:  Res Lett Biochem       Date:  2008-04-14

Review 5.  Fucanomics and galactanomics: marine distribution, medicinal impact, conceptions, and challenges.

Authors:  Vitor H Pomin
Journal:  Mar Drugs       Date:  2012-03-29       Impact factor: 6.085

6.  Different dose of heparin in preventing radial artery occlusion after transradial coronary angiography: A protocol for systematic review and meta-analysis of randomized controlled trials.

Authors:  Ling Zhao; Yanlei Pang; Huijing Zhang; Yong Li; Qun Zheng; Fengde Li
Journal:  Medicine (Baltimore)       Date:  2020-11-13       Impact factor: 1.889

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.